Purpose. We tested the hypothesis that prescription coverage affects the prescribing of long-acting opiates to indigent inner city minority patients with cancer pain.
complicated by other symptoms that must be considered using evidence-based standards in screening, assessment, and treatment [3] [4] [5] . Treatment must adopt a comprehensive approach that includes nonopiate analgesics, opiates, radiotherapy, psychosocial intervention, appropriate follow-up, and attention to associated comorbidities, including opiate-induced constipation [4, 5] . Nevertheless, the management of cancer pain in practice varies widely, where the burden of full diagnostic assessment may exceed potential benefits and patients require up front symptom relief [4] .
Assessment of cancer pain is an equally complicated and a variably practiced endeavor. Pain scales and assessment instruments have been constructed and validated [6] [7] [8] , and standards for the treatment of cancer pain have been generated and are in practice [9] . Despite these instruments, most pain assessment is done without much thought by many practitioners, and standards are often not included in the decision to assess pain [10, 11] . One approach, however, that of applying an analgesic protocol, was helpful in pain management [12, 13] .
Initially, cancer pain may be treated with acetaminophen or nonsteroidal anti-inflammatory agents, but opiates should be considered quickly [4] . While use of immediate release morphine may be adequate initially, the management of moderate to severe chronic pain should involve a relatively quick conversion to sustained release opiates [14, 15] . The use of transdermal Duragesic (fentanyl, Janssen Pharmaceuticals, Inc, Titusville, NJ, USA) and slow-release morphine is safe and has become standard therapy for cancer pain [16] . Patients receiving long-acting opiate formulations for noncancer pain showed improved treatment responses, a better perception of quality of life, improved focus on daily activities, less focus on pain, better pain regimen adherence, and reduced pain-related anxieties [17] .
Multiple factors affect the choices for managing pain by physicians, including issues involving the complex nature of cancer pain and its etiology, associated syndromes, associated comorbidities [3] , heritable factors [7] , history of substance use, physiologic, pharmacologic, psychosocial factors, and gender-and age-related factors [18] [19] [20] . Physician-related factors influence pain management decisions, which include training biases [21] , physician ethnic origin [22] , specialty training, and the nature and location of the medical facility [23] , among others. Patient ethnicity and societal effects significantly influence pain management [1, 2, 24] . Ethnic minorities are three times more likely to receive inadequate pain regimens than other patients [1] , with approximately two thirds of minority patients not receiving sufficient pain control as compared with half of nonminority patients [2, 23] . Specifically, 74% of Hispanic patients and 59% of African American patients did not receive adequate analgesia in one study [2] . We have previously demonstrated, in a pilot study, that indigent patients in an urban university hospital were prescribed appropriate long-acting analgesics for the treatment of cancer pain according to whether they had prescription coverage [25] . Here, we followed up these preliminary observations in a large-scale, definitive study to determine whether having a prescription plan affects the appropriate prescribing of long-acting opiates to indigent minority patients with cancer pain in an academic urban setting. Our data confirm that prescription benefits dictate the use of long-acting opiates in these patients.
Methods

Study Design, Patients, and Data Collection
We planned to test our hypothesis that uninsured indigent cancer patients are prescribed long-acting opiate analgesics at a lower rate than patients with unlimited prescription coverage with no deductible out-of-pocket costs using a retrospective chart review. We reviewed 180 charts of charity care/self-pay (CC/SP) patients and 180 charts of Medicaid patients who were followed in Medical Oncology Outpatient Practice and who met the criteria of receiving treatment for pain, having had a hospitalization, and three outpatient follow-up visits. There were no time limitations. The patients' payor status was determined by inspecting the University Hospital electronic medical records documentation. New Jersey State Charity Care status is awarded to patients by University Hospital after review of records to demonstrate lack of financial resources and of health insurance coverage. Charity care entitles patients to free medical care and treatment as inpatients or outpatients in our clinics. These patients have no prescription coverage and are responsible for paying for their own outpatient medications. We included the self-pay category of patients who are also indigent, uninsured, and without prescription coverage, but do not qualify for charity care due to a variety of issues, including United States residency status. After Institutional Review Board approval, a total of 360 charts of patients who met the above criteria were selected sequentially from July 5, 2000 to August 5, 2008 from Medical Oncology Outpatient Department appointment lists printed out randomly.
Data were collected on study sheets that requested a deidentified sequential patient number, age, gender, ethnicity or race, as identified by the medical record, payor status, smoking, alcohol or substance use as yes/no answers, disease, stage, and current therapy. The study sheets collected the date of discharge from hospitalization, level of pain reported from the traditional pain scale of 1-10 [8] , and analgesic medications and doses prescribed at hospital discharge. The data also included the dates of the three subsequent clinic visits, pain level, pain medications, patient adherence to the prescribed regimen at the time of the visit, and reasons for nonadherence. Any emergency department (ED) visits or unscheduled readmissions and the reasons were also recorded. Our primary endpoints were 1) difference in pain control between two payor groups on day 0, at first, second, and third visit; 2) differences between two payor groups in the change in pain control for each group between day 0 and first, second, and third visit, or a scheduled admission for chemotherapy; 3) differences in pain regimen between two payor groups on day 0 (use of long-acting opiates: 1 vs 0); 4) differences in adherence to pain regimen at first, second, and third visit, or scheduled admission for chemotherapy between two payor groups; 5) correlation between adherence to pain regimen (change in regimen) and change in pain control in each group; and 6) presence of confounding factors, such as differences in age and gender on the above end points. Secondary end points were 1) differences in the number of unscheduled emergency room (ER) visits between two payor groups and 2) differences in number of unscheduled hospitalizations for pain control or failure to thrive between two payor groups.
Statistical Analysis
Using the data from our pilot study of 40 patients [25] , we estimated that we would need to include 360 subjects divided equally between Medicaid and CC/SP in this definitive study to allow us to test for statistical significance of the logistic regression coefficients at the 5% level of significance with 80% power [26] . The estimates were based on an odds ratio of 2.5 when comparing severe pain to no pain in the Medicaid vs CC/SP patients [25] .
A widely used rule for judging the adequacy of the sample size for fitting a model is 10 events (lower frequency outcomes) per parameter. With 360 patients, we expected approximately 150 events (long acting prescriptions), giving the potential of a 15 parameter logistic regression model. Based upon the results of our pilot study, this was judged to be sufficient [27] . Chi-squared analysis was used to study the relationship between reported pain levels and demographics such as age, gender, and ethnicity. Repeated measures analysis of variance (ANOVA) was used to study the relationship between reported pain and disease stage and sequence number of the visit at which the pain report was recorded, hereafter referred to as the appointment number. Univariate and simpler bivariate analyses were carried out using chi-square and MannWhitney U-tests.
Results
Patient Characteristics
Age and gender distributions were statistically similar. The mean ages of CC/SP and Medicaid patients were 48.6 ± 13.9 and 48.6 ± 11.1, respectively, and both groups had 53.9% males and 46.1% females. The ethnic and racial distribution (P = 0.000), smoking (P = 0.000), and substance abuse rates (P = 0.008) were significantly different between the two payor groups by univariate chisquared analysis ( Table 1 ). The CC/SP group had disproportionately fewer African Americans, and the Medicaid group had disproportionately more African Americans than the average of the two groups combined (37.2% vs 57.8%) ( Table 1) . Conversely, the CC/SP group had a significantly higher representation of Hispanics, and the Medicaid group has fewer Hispanics than predicted (41.1% vs 25.6%). Caucasians were relatively evenly represented in the two groups at 13.9% compared with 11.1%, while CC/SP group had more Asians at 7.2% and the Medicaid group had fewer Asians at 2.8% (P = 0.000). There was a significantly lower smoking rate (24.0% vs 42.1%, P = 0.000) and substance abuse rate (4.9% vs 13.4%, P = 0.008) in the CC/SP group than in the Medicaid group by chi-squared analysis. Ethanol use was not statistically significant between the two groups ( Table 1) .
The same six tumor types, colorectal, head and neck, lung and breast carcinoma, and sarcoma, were the most frequently represented in both groups (Table 2 ). However, when comparing the frequency of tumors that occurred in at least five patients in both arms, head and neck, lung, breast and cervical carcinomas, sarcomas, and multiple myelomas were more prevalent in the Medicaid group, while colorectal and pancreatic carcinomas, germ cell tumors, and lymphomas were more common in the CC/SP group (P = 0.017, chi-square). In order to diminish the potential implications of this unbalance as a confounding factor, we stratified the tumor types by stage, which is one of the most significant factors in the odds ratio for occurrence of pain in the clinical setting of malignancies [28, 29] .
Indeed, the data demonstrate that patients with higher tumor stages were more highly represented in both payor groups receiving analgesic therapy, but the differences in tumor stage distributions were not statistically significant between the two groups ( Table 2 ). The percentages of patients receiving therapy for their disease during the sampling period were also similar, and the time to follow-up between discharge and the subsequent clinic visits were not statistically significant by a nonparametric test (Table 2) .
Pain Level
The frequency distribution of patients reporting a specific pain level did not differ significantly between the two groups by chi-squared analysis (P = 0.377) ( Table 3 ). The four pain assessments for each patient were averaged to reveal the single value reported in the table. The median pain levels in the two groups did not differ either when compared directly (P = 0.161). Median pain levels reported were similar in the two genders (P = 0.505) and the different ethnicities (P = 0.374) recorded by Mann-Whitney and chi-squared analysis (Table 3) . Similarly, none of the variables of age, gender, and ethnicity were significant predictors of pain level in chi-squared analyses ( Table 3 ). The lack of influence of ethnicity on pain level is particularly noteworthy, as it removes it as a confounding factor in the setting of the ethnic imbalance between the two payor groups.
For pain levels at stage vs each appointment, multivariate ANOVA with repeated measures for unbalanced designs was carried out. Stage did not affect the number of appointments attended (stage by appointment interaction, P = 0.551). The mean pain levels did not change significantly with subsequent appointment number in patients at the same stage (test for equal stage marginal means, P = 0.136). However, the average pain level did increase significantly with stage at each appointment, albeit not linearly (test for equal appointment marginal means, P = 0.000), in congruence with the increased numbers of patients being treated for pain with progressive stage (Table 2 ). There were no significant differences in mean pain levels at each visit between the payor groups either (not shown).
CC/SP patients visited the University Hospital ED at significantly lower rates than Medicaid patients (14.4% vs 23.9% of the patients, P = 0.023), with 54 vs 71 total ER visits for the two groups (P = 0.000). Of the reasons for the visits, 29 vs 56 of the visits in the two payor groups were for pain (Table 4) . However, a comparison of all the reasons for ER visits that were reported at least five times in each group did not yield a statistically significant difference (P = 0.737). While fewer CC/SP patients had unscheduled readmissions to University Hospital than Medicaid patients (29.4 vs 37.6%), the difference also did not reach statistical significance (P = 0.100) ( Table S1 ). CC/SP patients had 89 readmissions vs 114 in the Medicaid group (P = 0.079), but unlike ER visits, the causes of readmission were for a variety of medical problems as well as pain, and the differences between the most common reasons were not statistically significant (P = 0.463) ( Table S1 ).
Use of Long-Acting Opiates
The number of CC/SP patients who were prescribed longacting opiates at any time during the four encounters was significantly lower at 55 (30.6%) than the number of Medicaid patients at 98 (54.4%) (P = 0.000 Table 5 ). This difference was due to the significantly lower rate of use of all three long-acting opiates studied, Duragesic patches (P = 0.000), Oxycontin (P = 0.002; Purdue Pharma LP, Stamford, CT, USA), and MS Contin (P = 0.051; Purdue Pharma LP), by CC/SP patients than by Medicaid patients. Comparisons in rates of use were made between the number of patients prescribed each drug at any time and the number of patients who were never prescribed longacting opiates (125 for CC/SP and 82 for Medicaid patients). The median doses of the three drugs were not statistically different between the two payor groups (Table 5) . Methadone was rarely and inconsistently prescribed and was not included in the analysis. In line with the ethnic weighting of the two payor groups, Hispanic and Asian patients were prescribed long-acting opiates at a lower rate than that expected by the distribution of use in the entire sample (P = 0.027) ( Table 5 ). African Americans and Caucasians, on the other hand, were prescribed longacting opiates at a higher rate than the average rate of all the patients sampled. There were no differences in longacting opiate use between the genders (P = 0.448), and the number of patients adhering to the regimen at each follow-up visit did not differ between the two payor groups (P = 0.94). There were no differences in the change from use of long-term opiates from hospital discharge to clinic between the two groups (not at discharge → yes in clinic 22 vs 26, yes at discharge → no in clinic 9 vs 9). There was a significantly greater use of long-acting opiates with progressive stage in all patients (P = 0.006), SP/CC patients (P = 0.000), and Medicaid patients (P = 0.014) ( congruent with the increased levels of pain reported with progressive stage (Table 3) .
Multiple logistic regression of use of long-acting opiates on both benefits and ethnicity showed benefits to be the only statistically significant predictor (P = 0.006) ( Table 6 ).
Even while controlling for ethnicity, the odds of prescribing long-acting opiates for Medicaid patients was 2.4 times greater than the odds for CC/SP patients (P = 0.000). These data support our hypothesis that longacting opiate use in managing cancer pain in indigent patients is more frequent in patients who have Medicaid prescription coverage than CC/SP patients who have no prescription coverage.
Discussion
The data presented in this study support our hypothesis that indigent cancer patients treated in an inner city tertiary care medical center by medical oncologists have their pain treated differently depending on whether they have prescription coverage or not. Patients who have Medicaid prescription coverage received pain treatment with long-acting opiates at a far greater rate than did indigent patients who had no insurance or prescription coverage. There were some differences in the two groups that merit discussion, however. The CC/SP group had a disproportionately higher percentage of Hispanic and Asian patients while the Medicaid group had a significantly higher African American patient population. The distribution differences were likely due to United States residential status of the patients and their eligibility for Medicaid coverage. To provide support that this unbalance did not represent a confounding factor, we analyzed reported pain levels among the patients in the study and did not find statistically significant differences attributed to ethnicity. These findings are in agreement with reported pain assessment comparisons by patients and physicians, which found no differences between Hispanic and non-Hispanic Caucasian patients, even after controlling for multiple potential confounders [22] . A study of physicians' attitudes toward cancer pain provides further support for lack of effect of ethnicity [30] . In that study, similar rates of Hispanic patients (28%) as African American patients (31%) received analgesics of insufficient strength to manage their pain [30] . The data from our study showed that when treated individually in logistic regression analysis, both benefits and race had a statistically significant association with use of long-acting opiates (Table 6 ). However, logistic regression analysis demonstrated that the addition of race produced only a negligible improvement in the model of long-acting opiates as a function of benefits alone. The benefits category remains the dominant predictor of use of longacting opiates even when controlling for race and interaction of benefits and race (Table 5) .
Pain distributions in our two payor groups were statistically indistinguishable (Table 3) . This fact is a likely reflection on the payor category-independent attention to pain by the medical oncologist care providers in the practice, which ensured optimum pain control regardless of access to long-acting opiates. Nevertheless, the Medicaid group visited the ED at a higher rate, and many of those visits included pain as a reason. However, the frequency of the most common reasons for ER visits was not statistically different in the two payor groups (Table 4) . It is unclear whether the reasons for increased visits were financial, the influence of ethnic factors, or other unknown factors. The higher rate of substance use among the Medicaid patients in our study may suggest an additional potential reason for increased ED visits for pain. Others have also found that pain is among the top chief complaints of cancer patients visiting the ED and that 63% of visits result in admission to the hospital [31] . However, other medical issues are common and also result in hospitalizations [31] .
The rate of long-term analgesic use among all patients increased with progressive stage, corresponding to increased stage-associated pain levels. This suggests that the first inclination to prescribe affordable short-acting pain medications to uninsured patients was eventually trumped by an inflexible necessity to manage greater pain levels in later stages with long-acting opiates, despite the hardship of out of pocket costs to the uninsured patient (Table 5 ).
In conclusion, our data support our hypothesis that the use of standard of care long-acting opiates in indigent patients with cancer pain is significantly influenced by the availability of a prescription plan to the patient. 
